Debiopharm International SA-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013916)
◆英語タイトル:Debiopharm International SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013916
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:52
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for development. Debiopharm’s products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among others. The company offer products for the treatment of in vitro fertilization, metastatic colorectal cancer, advanced prostate cancer, precocious puberty, endometriosis, liver cancer, pancreatic cancer, uterine fibroids, severe sexual deviations and other diseases. It also develops drugs for indications in the therapeutic areas of infectious diseases and orphan drugs. The company provides licensing of products to pharmaceutical companies for marketing and sales. Debiopharm is headquartered in Lausanne, Switzerland.

Debiopharm International SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Debiopharm International SA, Medical Devices Deals, 2011 to YTD 2017 10
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Debiopharm International SA, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 14
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 15
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 16
Venture Financing 18
Spinomix Raises US$3 Million In Series A Financing 18
Biocartis Raises US$44.7 Million In Series D Financing 19
Biocartis Secures US$96 Million In Series C Financing Round 21
Partnerships 23
Debiopharm Partners with Merck and Pfizer 23
Debiopharm Enters into Distribution Agreement with Arbor Pharma 24
Debiopharm International Enters into Agreement with EORTC 25
United Labs Enters into Distribution Agreement with Debiopharm International 26
Debiopharm Enters into Agreement with Solid Biosciences 27
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 28
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 29
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 30
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 31
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 32
Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 33
Licensing Agreements 34
Debiopharm International Enters into Licensing Agreement with Almac Discovery 34
Evotec Enters Into Licensing Agreement With Debiopharm 35
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 36
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 37
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 38
Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 39
Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 40
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 41
Debiopharm International SA – Key Competitors 42
Debiopharm International SA – Key Employees 43
Debiopharm International SA – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Government and Public Interest 45
Jul 25, 2017: Debiopharm International Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea 45
Product News 46
10/25/2016: Debiopharm International Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450 46
04/08/2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID 47
01/10/2016: ImmunoGen Announces Update on IMGN529 and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference 48
Clinical Trials 50
Jan 10, 2017: Debiopharm International Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients 50
Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Debiopharm International SA, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Debiopharm International SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Debiopharm International SA, Deals By Therapy Area, 2011 to YTD 2017 9
Debiopharm International SA, Medical Devices Deals, 2011 to YTD 2017 10
Debiopharm International SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 14
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 15
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 16
Spinomix Raises US$3 Million In Series A Financing 18
Biocartis Raises US$44.7 Million In Series D Financing 19
Biocartis Secures US$96 Million In Series C Financing Round 21
Debiopharm Partners with Merck and Pfizer 23
Debiopharm Enters into Distribution Agreement with Arbor Pharma 24
Debiopharm International Enters into Agreement with EORTC 25
United Labs Enters into Distribution Agreement with Debiopharm International 26
Debiopharm Enters into Agreement with Solid Biosciences 27
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 28
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 29
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 30
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 31
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 32
Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 33
Debiopharm International Enters into Licensing Agreement with Almac Discovery 34
Evotec Enters Into Licensing Agreement With Debiopharm 35
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 36
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 37
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 38
Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 39
Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 40
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 41
Debiopharm International SA, Key Competitors 42
Debiopharm International SA, Key Employees 43
Debiopharm International SA, Subsidiaries 44

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Debiopharm International SA-製薬・医療分野:企業M&A・提携分析(Debiopharm International SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆